Drug Development Pipeline

Identifying Targets and Therapies

In the past, few companies have invested in chronic and recurrent acute pancreatitis therapies, in part because researchers did not know what was causing the inflammation of the pancreas. Now, scientists are learning more about what causes the inflammation in many patients. When we know what biological processes are going wrong (called β€œtargets”), researchers can work to identify therapies that will correct the problem.

Our Targets

Target DiscoveryTherapeutic DiscoveryPreclinical ResearchClinical Research
Fibrosis/TRAILβ˜‘β˜‘β˜‘β˜‘
Fibrosis/CCK Receptorβ˜‘β˜‘β˜‘β˜‘
Vitamin D Receptorβ˜‘β˜‘β˜‘β˜‘
Painβ˜‘β˜‘β˜‘β˜‘
Stem Cellsβ˜‘β˜‘β˜‘β˜‘
CFTRβ˜‘β˜‘β˜‘β€“
PRSS1β˜‘β˜‘β˜‘β€“
SPINK1β˜‘β˜‘β˜‘β€“
CA 19-9β˜‘β˜‘β˜‘β€“
FGF21β˜‘β˜‘β˜‘β€“
T3Dβ˜‘β˜‘β€“β€“
Scroll to Top

Before You Go

Get Updates in Your Inbox

Stay up-to-date on the latest Mission: Cure news and developments in pancreatitis care.







I am a...: